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2142Atrial ﬁbrillation (AF) is a potent
risk factor for stroke. Warfarin is
highly efﬁcacious in reducing this
risk, but its effectiveness in clin-
ical practice is challenged by its
variable dose response, need for
frequent monitoring, and associ-
ated risk of hemorrhage. Among
patients age 65 years or older,
warfarin was noted to be the
drug most often implicated in
medication-related adverse events
leading to emergency hospitalstay (1). Apixaban, a factor Xa inhibitor, was shown to
reduce the risk of major hemorrhage by 31% compared
with warfarin among patients with AF in the ARIS-
TOTLE (Apixaban for Reduction in Stroke and Otherpage 2148Thromboembolic Events in Atrial Fibrillation) trial (2).
In this report, we sought to: 1) deﬁne 30-day mortality
after a major bleeding event and determine whether this
factor differed between warfarin- and apixaban-treated
patients; 2) identify predictors of major bleeding and
determine whether predictors of major bleeding varied
between warfarin- and apixaban-treated patients; 3) further
characterize the reduction in major bleeding based on the
components of the major bleeding deﬁnition and determine
whether these components varied between warfarin- and
apixaban-treated patients; and 4) explore major bleeding
by location and determine whether bleeding locations
varied between warfarin- and apixaban-treated patients.
Methods
The ARISTOTLE trial design has been reported previ-
ously (3). Patients with AF and at least 1 risk factor for
stroke were randomized to receive either dose-adjusted
warfarin or apixaban, 5 mg twice daily. A reduced dose of
apixaban, 2.5 mg twice daily, was designated for participants
with 2 or more of the following criteria: age 80 years,
weight 60 kg, or serum creatinine concentration 1.5
mg/dl (133 mmol/l). The reduced dose of apixaban was
administered to 428 patients (4.7%). To enhance the
quality of warfarin management, a dosage algorithm was
provided, and a program implemented to provide regular
feedback to sites regarding their level of international
normalized ratio (INR) control.; consulting fees from Merck & Co, Regado
Behring, Athera Biotechnologies, Boehringer
Kline, and Bristol-Myers Squibb/Pﬁzer; lecture
ngelheim, Bristol-Myers Squibb/Pﬁzer, Glaxo-
raria from Boehringer Ingelheim, AstraZeneca,
ithKline, and Merck & Co; and travel support
Squibb/Pﬁzer. Dr. Granger has received grants
Myers Squibb, GlaxoSmithKline, MedtronicThe analyses of bleeding events included all patients who
received at least 1 dose of a study drug and included all
events from the time of the ﬁrst dose until 2 days after the
last dose was received. Major bleeding was deﬁned according
to International Society on Thrombosis and Haemostasis
(ISTH) criteria as clinically overt bleeding accompanied by a
decrease in the hemoglobin level of at least 2 g/dl or
transfusion of at least 2 units of packed red cells, occurring at
a critical site (intracranial, intraocular, intraspinal, intra-
articular, intramuscular with compartment syndrome, peri-
cardial, retroperitoneal), or resulting in death (4). No time
restrictions were applied to this deﬁnition. Laboratory and
transfusion data coupled with clinical event details were used
to identify and adjudicate potential bleeding events. Routine
collection of hemoglobin occurred every 3 months. Location
of bleeding was extracted from the case report form. Addi-
tional source documents were collected when necessary. The
primary safety outcomes were adjudicated on the basis of
pre-speciﬁed criteria by a clinical events committee whose
members were not aware of study group assignments.
Severity of hemorrhage and 30-day mortality following
ﬁrst ISTH major hemorrhage. Parameters to assess the
severity of major hemorrhage, in addition to anatomic
location, for apixaban and warfarin were determined and
compared. Metrics relevant for major extracranial hemor-
rhage included decrease of hemoglobin of at least 2 g/dl,
hospitalization because of bleeding, transfusion of packed
red cells, number of units transfused, medical or surgical
consultation or evaluation, medical or surgical intervention
to stop the bleeding, hemodynamic compromise, and change
in antithrombotic therapy. Thirty-day mortality rates
following ﬁrst ISTH major hemorrhage were evaluated and
compared between warfarin- and apixaban-treated patients.
Statistical analyses. Categorical variables were summarized
as frequencies and percentages and continuous variables as
medians and 25th and 75th percentiles. p Values repre-
senting comparisons between patients with and without
major bleeding were based on Cox regression models with
ISTH criteria ﬁrst major hemorrhage as a dependent vari-
able. p Values for the interactions between randomized
treatment and each covariate were derived using Cox
models. Factors associated with the ﬁrst ISTH major
hemorrhage were identiﬁed using a multivariable Cox
model. Candidate variables included demographics and
clinical characteristics, medications, and laboratory values at
baseline. Randomized treatment and region of enrollment
were also included as candidate variables. Missing values
in predictors were imputed using multiple imputations.Foundation, Merck & Co, Pﬁzer, Sanoﬁ-Aventis, Takeda, and The Medicines
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Table 1 Baseline Characteristics
ISTH Major Bleeding ¼ Yes ISTH Major Bleeding ¼ No
p Value*
Interaction
p Valuey
Overall
(n ¼ 789)
Apixaban
(n ¼ 327)
Warfarin
(n ¼ 462)
Overall
(n ¼ 17,351)
Apixaban
(n ¼ 8761)
Warfarin
(n ¼ 8590)
Age, yrs 74 (68, 79) 74 (67, 79) 74 (68, 79) 70 (62, 76) 70 (63, 76) 70 (62, 76) <0.001 0.50
Female (%) 270 (34.2) 102 (31.2) 168 (36.4) 6,123 (35.3) 3,118 (35.6) 3,005 (35.0) 0.84 0.084
Systolic BP, mm Hg 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 0.16 0.36
Weight, kg 80 (68, 93) 83 (70, 94) 78 (67, 91) 82 (70, 96) 82 (70, 96) 82 (70, 96) <0.001 0.012
Prior MI (%) 143 (18.1) 61 (18.7) 82 (17.8) 2,437 (14.1) 1,257 (14.4) 1,180 (13.8) 0.003 0.78
Prior clinically relevant or spontaneous
bleeding episodes (%)
186 (23.6) 82 (25.2) 104 (22.5) 2,847 (16.4) 1,442 (16.5) 1,405 (16.4) <0.001 0.33
History of falls within previous year (%) 57 (7.9) 26 (8.7) 31 (7.4) 695 (4.4) 360 (4.5) 335 (4.3) <0.001 0.57
Type of AF (%) 0.078 0.75
Paroxysmal 104 (13.2) 44 (13.5) 60 (13.0) 2,672 (15.4) 1,327 (15.1) 1,345 (15.7)
Persistent or permanent 685 (86.8) 283 (86.5) 402 (87.0) 14,676 (84.6) 7,432 (84.9) 7,244 (84.3)
Qualifying risk factors (%)
Age 75 yrs 375 (47.5) 151 (46.2) 224 (48.5) 5,280 (30.4) 2,685 (30.7) 2,595 (30.2) <0.001 0.39
Prior stroke, TIA, or SE 188 (23.8) 80 (24.5) 108 (23.4) 3,335 (19.2) 1,660 (18.9) 1,675 (19.5) 0.001 0.61
HF or reduced LVEF 275 (34.9) 112 (34.2) 163 (35.3) 6,160 (35.5) 3,115 (35.6) 3,045 (35.4) 0.75 0.74
Diabetes 226 (28.6) 112 (34.2) 114 (24.7) 4,300 (24.8) 2,164 (24.7) 2,136 (24.9) 0.0056 0.0034
Hypertension requiring treatment 671 (85.0) 277 (84.7) 394 (85.3) 15,188 (87.5) 7,655 (87.4) 7,533 (87.7) 0.028 0.96
Medications at randomization (%)
Amiodarone 82 (10.6) 31 (9.6) 51 (11.4) 1,965 (11.5) 974 (11.3) 991 (11.7) 0.63 0.49
Aspirin 254 (32.2) 115 (35.2) 139 (30.1) 4,159 (24.1) 2,107 (24.1) 2,052 (24.0) <0.001 0.19
Clopidogrel 25 (3.2) 11 (3.4) 14 (3.0) 312 (1.8) 158 (1.8) 154 (1.8) 0.0026 0.80
Statin 381 (46.8) 157 (48.5) 204 (45.5) 7,081 (41.5) 3,579 (41.6) 3,502 (41.3) 0.0043 0.36
NSAIDs 100 (13.0) 40 (12.3) 60 (13.4) 1,418 (8.3) 711 (8.3) 707 (8.3) <0.001 0.69
Gastric antacid drugs 197 (25.5) 86 (26.5) 111 (24.8) 3,139 (18.4) 1,589 (18.5) 1,550 (18.3) <0.001 0.62
Renal function covariates (%) <0.001 0.042
Normal (>80 ml/min) 215 (27.3) 96 (29.5) 119 (25.9) 7,281 (42.1) 3,654 (41.9) 3,627 (42.4)
Mild impairment (>50–80 ml/min) 356 (45.3) 157 (48.2) 199 (43.3) 7,209 (41.7) 3,650 (41.8) 3,559 (41.6)
Moderate impairment (>30–50 ml/min) 189 (24.1) 66 (20.2) 123 (26.7) 2,548 (14.8) 1,291 (14.8) 1,257 (14.7)
Severe impairment (30 ml/min) 26 (3.3) 7 (2.1) 19 (4.1) 242 (1.4) 129 (1.5) 113 (1.3)
Liver dysfunction (%) 8 (1.0) 4 (1.2) 4 (0.9) 505 (2.9) 261 (3.0) 244 (2.8) 0.0024 0.68
Hematocrit 42.0 (38.6, 45.0) 42.0 (38.2, 45.0) 42.0 (38.9, 45.0) 43.0 (40.0, 46.0) 43.0 (40.0, 46.0) 43.0 (40.0, 46.0) <0.001 0.60
Platelet count, 109/l 211 (176, 253) 207 (172, 249) 213 (180, 255) 211 (178, 250) 210 (177, 249) 212 (179, 251) 0.83 0.45
Values are median (25th, 75th percentile) or n (%). *p value comparing patients with and without ISTH major bleeding. yp value for treatment by covariable interaction.
AF ¼ atrial ﬁbrillation; BP ¼ blood pressure; HF ¼ heart failure; ISTH ¼ International Society on Thrombosis and Haemostasis; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; SE ¼ systemic embolism;
TIA ¼ transient ischemic attack.
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2144Missing values were uncommon (<3%) for all predictors,
except for history of fall (9%). Twenty-ﬁve imputed datasets
were generated, and a stepwise selection method was used in
each dataset. Predictors selected in more than 80% of the
imputed datasets were included in the ﬁnal model. We
tested for interactions between variables in the ﬁnal model
and randomized treatment.
Four additional endpoints were deﬁned according to the
consequences of hemorrhage, including major extracranial
hemorrhage, followed by hospitalization, medical or surgical
intervention, transfusion, and change in antithrombotic
therapy. These endpoints were summarized overall and by
randomized treatment as rates (except for the number of
units of packed cells transfused), number of events, and
hazard ratios (HR) comparing all patients randomized to
apixaban versus those to warfarin. All statistical analyses
were performed using SAS version 9.2 software (SAS
Institute, Inc., Cary, North Carolina).
Results
As previously reported, the ARISTOTLE trial enrolled
18,201 patients from 1,034 clinical sites in 39 countries. The
on-treatment safety population included 18,140 patients.
The median follow-up time was 20.5 months. Major
hemorrhage occurred in 789 patients (4.3%) overall; 327 in
the apixaban group (2.13% per year) compared with 462 in
the warfarin group (3.09% per year; HR 0.69, 95% conﬁ-
dence interval [CI]: 0.60 to 0.80; p < 0.001). Patients who
sustained a major bleed were older (74 vs. 70 years,
respectively), more commonly had a history of myocardial
infarction, prior hemorrhage, impaired renal function, and a
fall within the previous year compared with patients withoutTable 2 Major Bleeding by Location (First Major Hemorrhage at Eac
Location
Overall
(n ¼ 18,140)
Apixaban
(n ¼ 9088)
Intracranial 0.57 (174) 0.33 (52)
Intra-articular 0.05 (16) 0.04 (6)
Digestive tract 0.83 (254) 0.78 (121)
Upper gastrointestinal 0.49 (151) 0.43 (66)
Lower gastrointestinal 0.24 (75) 0.25 (39)
Hemorrhoidal 0.02 (7) 0.03 (4)
Rectal 0.08 (26) 0.09 (14)
Hemoptysis 0.01 (4) 0.01 (1)
Hemothorax 0.02 (5) 0.01 (2)
Intramuscular 0.01 (2) 0.01 (1)
Bruising/ecchymosis 0.04 (11) 0.02 (3)
Epistaxis 0.07 (23) 0.08 (12)
Retroperitoneal 0.02 (7) 0.01 (2)
Intraspinal 0.01 (4) 0.01 (2)
Vaginal 0.02 (7) 0.03 (5)
Hematoma 0.25 (78) 0.16 (25)
Hematuria 0.14 (42) 0.13 (20)
Intraocular 0.15 (47) 0.18 (28)
Values are rate (per 100 patient-years of follow-up) (number of events). *p values compare apixaban to
CI ¼ conﬁdence interval; HR ¼ hazard ratio.ISTH major hemorrhage (Table 1). They also weighed less
and had a lower hematocrit level at baseline. Among the
qualifying risk factors, patients who sustained a major
hemorrhage were more likely to have a history of stroke,
transient ischemic attack (TIA) or systemic embolism, dia-
betes, or hypertension. They were also more likely to use
aspirin, clopidogrel, nonsteroidal anti-inﬂammatory drugs,
statins, and gastric antacid drugs at baseline.
Location of hemorrhage. The most frequent sites of major
hemorrhage were gastrointestinal (31%; n ¼ 248), intra-
cranial (22%; n ¼ 171), and soft tissue (10%; n ¼ 75)
(Table 2). Two-thirds of the gastrointestinal bleeds involved
the upper tract. Apixaban was associated with fewer
gastrointestinal hemorrhages than warfarin, but this differ-
ence did not achieve statistical signiﬁcance (HR 0.89, 95%
CI: 0.70 to 1.14). There were also fewer soft tissue hema-
tomas associated with apixaban that met the criteria for
ISTH major hemorrhage (HR 0.46, 95% CI: 0.29 to 0.74).
In addition, apixaban was associated with fewer major
hemorrhages related to trauma: 37 in the apixaban group
(0.24% per year) compared with 60 in the warfarin group
(0.40% per year; HR 0.60, 95% CI: 0.40 to 0.91;
p ¼ 0.015). As previously reported, apixaban was associated
with fewer intracranial hemorrhages than warfarin (HR
0.42, 95% CI: 0.30 to 0.58).
Severity and short-term consequences of hemorrhage.
Major extracranial hemorrhage-associated adverse conse-
quences occurred less frequently in the apixaban group than in
the warfarin group, including fewer hospitalizations (HR:
0.75, 95% CI: 0.61 to 0.92), fewer medical or surgical in-
terventions to stop the bleeding (HR: 0.72, 95% CI: 0.56 to
0.93), fewer transfusions (HR: 0.71, 95% CI: 0.57 to 0.89),
and fewer changes in antithrombotic therapy (HR: 0.78, 95%h Location)
Warfarin
(n ¼ 9052)
Apixaban vs. Warfarin
HR (95% CI) p Value*
0.80 (122) 0.42 (0.30–0.58) <0.001
0.07 (10) 0.59 (0.21–1.61) 0.30
0.88 (133) 0.89 (0.70–1.14) 0.35
0.56 (85) 0.76 (0.55–1.05) 0.094
0.24 (36) 1.06 (0.67–1.67) 0.80
0.02 (3) 1.31 (0.29–5.83) 0.73
0.08 (12) 1.14 (0.53–2.47) 0.74
0.02 (3) 0.33 (0.03–3.15) 0.33
0.02 (3) 0.66 (0.11–3.92) 0.64
0.01 (1) 0.98 (0.06–15.60) 0.99
0.05 (8) 0.37 (0.10–1.38) 0.14
0.07 (11) 1.06 (0.47–2.41) 0.88
0.03 (5) 0.39 (0.08–2.02) 0.26
0.01 (2) 0.98 (0.14–6.97) 0.99
0.01 (2) 2.46 (0.48–12.68) 0.28
0.35 (53) 0.46 (0.29–0.74) 0.0015
0.14 (22) 0.89 (0.49–1.63) 0.71
0.13 (19) 1.45 (0.81–2.59) 0.21
warfarin rates of bleeding.
Figure 1 Major Bleeding Following by Death Within 30 Days
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
JACC Vol. 63, No. 20, 2014 Hylek et al.
May 27, 2014:2141–7 Risk Factors for Anticoagulation in Atrial Fibrillation: A Dilemma
2145CI: 0.64 to 0.95) (Table 3). Major ISTH hemorrhage criteria
followed by death within 30 days occurred half as often in the
apixaban group compared with the warfarin group, with 36
and 71 events, respectively (HR: 0.50, 95% CI: 0.33 to 0.74;
p < 0.001) (Fig. 1).
Independent factors associated with ﬁrst major
hemorrhage. Older age, prior hemorrhage, prior stroke or
TIA, diabetes, lower creatinine clearance (5), and decreased
hematocrit level were independently associated with an
increased risk of major hemorrhage (Table 4). Use of aspirin
and nonsteroidal anti-inﬂammatory drugs also indepen-
dently increased the risk of major bleeding by approximately
30%. In the multivariable models, randomization to apix-
aban, compared with warfarin, was associated with a lower
risk of major hemorrhage (HR: 0.69, 95% CI: 0.60 to 0.72),
as was female sex and liver disease.
In an exploratory analysis of subgroup by treatment in-
teractions, we found a differential effect by treatment ac-
cording to 3 variables: baseline renal function, weight, and
diabetes. For patients with renal dysfunction and low body
weight, the reduction in bleeding with apixaban appeared to
be greater than in patients with normal renal function and
higher body weight than in patients taking warfarin. For
patients with diabetes, the reduction in bleeding with
apixaban appeared to be less than for patients without
diabetes.Discussion
In the ARISTOTLE trial, there were fewer intracranial
hemorrhages on apixaban, fewer adverse consequences of
extracranial hemorrhages, and fewer trauma-related hem-
orrhages. Apixaban, compared with warfarin, was associated
with 50% less ISTH major hemorrhage leading to death
within 30 days after the event. Warfarin treatment was
more often associated with bleeding requiring hospitaliza-
tion, transfusion, procedures to stop bleeding, and change
in antithrombotic therapy, all of which may have contrib-
uted to the differences in severity and mortality. Although
the mechanisms underlying these differences are unknown,
the prolonged half-life of warfarin and warfarin’s suppres-
sion of factor VIIa may be implicated; an active factor VIIaTable 3 Characteristics of Major Extracranial Hemorrhage
Overall
(n ¼ 18,140)
Apixab
(n ¼ 90
Led to hospitalization 1.23 (374) 1.05 (1
Fall in hemoglobin 2 g/dl 1.25 (381) 1.06 (1
Led to transfusion 1.06 (325) 0.89 (1
Required medical or surgical consultation 1.74 (527) 1.54 (2
Required medical or surgical intervention
to stop
0.77 (236) 0.65 (1
Associated with hemodynamic compromise 0.32 (97) 0.26 (4
Caused changed in antithrombotic therapy 1.31 (398) 1.14 (1
Values are rate (per 100 patient-years of follow-up) (number of events). *p values compare apixaban to
Abbreviations as in Table 2.and tissue factor complex are necessary to initiate hemo-
stasis (6). Although reversal of warfarin with vitamin K,
fresh frozen plasma, prothrombin complex concentrates, or
recombinant factor VIIa has been shown to reduce the INR,
the effects of these interventions on clinical outcomes are
uncertain. Delays in presentation, infusion delays, incom-
plete INR correction, and prothrombotic risk all undermine
the effectiveness of these agents in routine practice (7–9). In
the ARISTOTLE trial, warfarin-associated major hemor-
rhage also more often triggered a change in antithrombotic
therapy. Cessation of warfarin therapy was recently shown
to increase the risk of thrombosis and death among in-
dividuals who had sustained a gastrointestinal hemorrhage
(10). A better understanding of the sequelae of major hem-
orrhage in terms of intervention, treatment, and attendant
complications would inform its optimal management in
clinical practice.
Our ﬁndings for independent factors associated with
major hemorrhage underscore the challenge of shared risk
factors for stroke and hemorrhage among individuals with
AF, especially those who are older and have had prior stroke
and renal dysfunction (11–16). Our ﬁndings also highlightan
88)
Warfarin
(n ¼ 9052)
Apixaban vs. Warfarin
HR (95% CI) p Value*
62) 1.41 (212) 0.75 (0.61–0.92) 0.0052
64) 1.44 (217) 0.74 (0.60–0.91) 0.0035
37) 1.25 (188) 0.71 (0.57–0.89) 0.0025
36) 1.94 (291) 0.79 (0.67–0.94) 0.0080
00) 0.90 (136) 0.72 (0.56–0.93) 0.012
0) 0.38 (57) 0.69 (0.46–1.029) 0.069
76) 1.47 (222) 0.78 (0.64–0.95) 0.012
warfarin rates of bleeding.
Table 4 Baseline Factors Independently Associated With Major Hemorrhage*
Parameter Chi-Square Value p Value HR Represents HR (95% CI)
Hematocrit (<45%) 38.5 <0.001 5-U decrease (under 45) 1.38 (1.24–1.52)
Age 35.3 <0.001 10-yr increase 1.36 (1.23–1.51)
Randomized treatment 26.8 <0.001 Apixaban vs. warfarin 0.69 (0.60–0.79)
Creatinine clearance (<85 ml/min/1.73 m2) 16.9 <0.001 10-U decrease (under 85) 1.11 (1.058–1.17)
Sex 14.2 0.002 Female vs. male 0.74 (0.63–0.87)
History of bleeding 14.2 0.002 Yes vs. no 1.38 (1.17–1.63)
Aspirin at randomization 13.5 0.002 Yes vs. no 1.31 (1.14–1.52)
Diabetes 7.3 0.0067 Yes vs. no 1.24 (1.062–1.45)
NSAIDs at randomization 6.7 0.0096 Yes vs. no 1.33 (1.072–1.65)
Prior stroke/TIA/SE 5.8 0.016 Yes vs. no 1.23 (1.038–1.45)
Liver disease 5.4 0.020 Yes vs. no 0.44 (0.22–0.88)
*C-index: 0.68. Region of enrollment was included in the model.
NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; SE ¼ systemic embolism; TIA ¼ transient ischemic attack; other abbreviations as in Table 2.
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among individuals with a propensity for hemorrhage, as
those individuals with a prior episode are at highest risk for
recurrence. Because of the substantial overlap in risk factors
and the major disability related to ischemic stroke, reliance
on currently available hemorrhage risk scores for decisions
regarding anticoagulant therapy is problematic. These scores
were not derived to predict intracranial hemorrhage but
rather a wide spectrum of hemorrhagic complications, most
of which do not render permanent sequelae. The inability to
account for aspirin and nonprescription nonsteroidal anti-
inﬂammatory drugs is another limitation (13,17). Use of
these tools to identify modiﬁable risk factors amenable to
intervention will translate into fewer hemorrhages and
improved long-term persistence with anticoagulant therapy.
The potent deleterious effects of antiplatelet drugs and
nonsteroidal anti-inﬂammatory agents urge caution with
concomitant use and vigilance regarding indication and
duration of therapy (18,19). Alternative analgesic medica-
tions without the attendant effects on platelets and gastric
mucosa are needed for this patient population. Ascertain-
ment of any protective effect of gastric acid suppressants in
this setting requires randomized assessment. Similar to the
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) trial and the studies by Beyth et al.
(12) and Shireman et al. (20), we also found diabetes mel-
litus to be an independent risk factor for major hemorrhage
(15). The independent contribution of diabetes mellitus may
be obscured by renal dysfunction, given their expected high
degree of correlation. Microalbuminuria has been associated
with both intracerebral hemorrhage and hematuria (21,22).
Hypertension was not found to be an independent predictor
of major hemorrhage in ARISTOTLE, which may reﬂect
the degree of blood pressure control achieved among trial
participants. The lower rate of major bleeding in females has
not been previously reported and warrants further study.
Only 8 patients with liver dysfunction experienced a major
hemorrhage, precluding any deﬁnitive conclusion regarding
this patient subgroup.Study limitations. The objective of a randomized trial is to
provide the most valid, unbiased estimate of medication
effect. For this reason, individuals with anticipated difﬁculty
with study protocols or with heightened risk of short
exposures (adherence, excessive risk of hemorrhage) may be
underrepresented. Thus, extrapolation of trial results to these
populations should be done cautiously. However, rates of
major hemorrhage associated with warfarin in contemporary
AF trials are 2- to 3-fold higher than the rates reported in
earlier studies, likely reﬂecting the older age of today’s trial
participants, the higher prevalence of chronic disease and
concomitant aspirin use, and the overall broader prescription
of anticoagulant medications in current AF populations
(23–27). Thus, we believe our trial participants are repre-
sentative of most patients with AF in clinical practice.
Conclusions
Compared with warfarin, apixaban was associated with a
31% reduction in risk of ﬁrst major ISTH hemorrhage.
Apixaban was associated with fewer intracranial hemor-
rhages, fewer adverse consequences following extracranial
hemorrhages, fewer trauma-associated hemorrhages, and a
50% reduction in fatal consequences at 30 days in case of a
major hemorrhage. Therefore, concerns for complications in
case of hemorrhage during anticoagulant treatment are fewer
during apixaban than warfarin treatment.
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